“JM Financial holds the highest price target for Neuland Laboratories at ₹25,819, implying a significant upside potential from current levels. This bullish stance is likely driven by the company's strong Q1 results, which exceeded analyst expectations with substantial year-on-year growth in revenue, EBITDA, and net profit, despite sequential declines attributed to the lumpy nature of the CDMO business.”

JM Financial Analysis’s track record: 4 graded calls · 95% CI 5–70%